We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Pharmacotherapy of Insomnia: Focus on Zolpidem Extended Release
PeriodicalsMedical Sciences

Pharmacotherapy of Insomnia: Focus on Zolpidem Extended Release

Checking your access to this record.

Abstract & Overview

The imidazopyridine drug zolpidem ( N,N,6-trimethyl-2[4-methyl-phenyl]imidazo[1,2-a]pyridine-3-acetamide) is a sedative/hypnotic with relative selectivity for α1subunits of the GABAAreceptor/chloride channel complex. Because of this selectivity and regional receptor distribution, zolpidem is less generalized in its CNS depressive actions than benzodiazepines and largely devoid of their major, undesired side- and after-effects, at recommended doses. Zolpidem is rapidly taken up and distributed, binds extensively to plasma proteins, and is readily inactivated by hepatic cytochrome P450monooxygenases, especially CYP3A4. Zolpidem is thus a rapidly acting agent which provides effective facilitation of sleep onset. However, plasma levels of the immediate release (IR) formulation frequently decline too quickly for effective sleep maintenance. To address this problem zolpidem extended release (ER) has been developed. At age-specific dosages, it increases, in middle-aged and elderly patients, total sleep time and reduces the number of nocturnal awakenings. Both zolpidem IR and ER have favorable toxicological profiles. Adverse effects are moderate, frequently in the incidence range of placebos, and certainly less frequent and severe than those of benzodiazepines. Zolpidem IR and ER are practically devoid of next-day hangover effects and only infrequently cause rebound insomnia of usually short duration. Both variants of zolpidem have a limited potential for dependence and abuse.

Cite this record

Jaime M. Monti, D. Warren Spence, Seithikurippu Ratnas Pandi-Perumal, Salomón Z. Langer, Rüdiger Hardeland (2009). Pharmacotherapy of Insomnia: Focus on Zolpidem Extended Release. Clinical Medicine Therapeutics, 1. https://doi.org/10.4137/cmt.s2040

Copy in another style

Monti, J. M., Spence, D. W., Pandi-Perumal, S. R., Langer, S. Z., & Hardeland, R. (2009). Pharmacotherapy of Insomnia: Focus on Zolpidem Extended Release. Clinical Medicine Therapeutics, 1. https://doi.org/10.4137/cmt.s2040
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.